Health ❯Public Health ❯HIV/AIDS

Prevention

HIV/AIDS Infectious Diseases Public Policy LGBTQ+ Rights Global Health Federal Government Peer Review Public Health Trump Administration Government Agencies

FDA to Decide on Twice-Yearly HIV Preventive Drug Lenacapavir

Generic manufacturers are set to produce lenacapavir for as little as $25 per patient annually

Trump Administration Weighs Major Cuts to HIV Prevention Programs

Annual HIV Prevention Injection Shows Promise in Early Safety Trials

CDC Removes HIV Resources Following Trump Administration Order Targeting Gender Ideology